Peritoneal (Abdominal Mesothelioma)
NR4A3 fusions characterize a distinctive peritoneal mesothelial neoplasm of uncertain biological potential with pure adenomatoid/microcystic morphology
Genes, Chromosomes, and Cancer 2022 December 16 [Link] Abbas Agaimy, Luka Brcic, Laurence M Briski, Yin P Hung, Michael Michal, Michal Michal, G Petur Nielsen, Robert Stoehr, Andrew E Rosenberg Abstract A focal adenomatoid-microcystic pattern is not uncommon in peritoneal mesothelioma, but tumors composed almost exclusively of this pattern are distinctly rare and have not…
Read MoreExtensive Peritonectomy is an Independent Risk Factor for Cisplatin HIPEC-Induced Acute Kidney Injury
Annals of Surgical Oncology 2022 December 10 [Link] Lukas F Liesenfeld, Eva Quiring, Mohammed Al-Saeedi, Christian Nusshag, Markus W Büchler, Martin Schneider Abstract Background: Cisplatin (CDDP)-containing hyperthermic intraperitoneal chemotherapy (HIPEC) is frequently applied in selected patients with peritoneal malignancies derived from ovarian cancer, gastric cancer, and primary peritoneal mesothelioma. HIPEC with CDDP increases perioperative morbidity,…
Read MoreHistopathological and immunohistochemical features of 14 peritoneal mesotheliomas with clinical outcomes and recent updates
Journal of Cancer Research and Therapeutics 2022 Oct-Dec [Link] Srushti Karmarkar, Bharat Rekhi, Kedar K Deodhar, Santosh Menon Abstract Background: Malignant peritoneal mesotheliomas (MPMs) are rare tumors with overlapping clinical and histopathological features, especially with epithelial ovarian carcinomas (EOCs). There is no substantial documentation on these rare tumors from our country. Objective: To study the…
Read MoreAnti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures
Proceedings of the National Academy of Sciences of the United States of America 2022 November 29 [Link] Wenlong Liu, Chin-Hsien Tai, Xiufen Liu, Ira Pastan Abstract LMB-100 is a recombinant immunotoxin composed of a Fab linked to a toxin. It kills cells expressing human mesothelin (hMSLN), which is highly expressed on the surface of mesothelioma…
Read MoreProtocol for a prospective observational cohort study collecting data on demographics, symptoms and biomarkers in people with mesothelioma (ASSESS-meso)
BMJ Open 2022 November 10 [Link] Ruairi J H Conway, Jenny Symonds, Deborah Walton, Janet Probets, Charles Comins, Louise Stadon, John E Harvey, Kevin G Blyth, Nick A Maskell, Anna C Bibby Abstract Introduction: Mesothelioma is a heterogeneous disease that can be challenging to monitor and prognosticate. ASSESS-meso is a multicentre, prospective, longitudinal observational cohort…
Read MoreMalignant Peritoneal Mesothelioma Features Shown by FDG-PET/CT
Cancer Diagnosis & Prognosis 2022 November 3 [Link] Kozo Kuribayashi, Kazuhiro Kitajima, Toshiyuki Minami, Masataka Ikeda, Koichiro Yamakado, Takashi Kijima Abstract Background/aim: Malignant peritoneal meso-thelioma (MPeM) has no specific imaging findings that can distinguish it from other peritoneal tumors and the accuracy of peritoneal cytology is low, therefore definitive diagnosis is usually performed by histology.…
Read MoreConditional Survival Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: An Analysis from the US HIPEC Collaborative
Annals of Surgical Oncology 2022 October 30 [Link] Eliza W Beal, Shruthi Srinivas, Chengli Shen, Alex Kim, Fabian M Johnston, Jonathan Greer, Daniel E Abbott, Courtney Pokrzywa, Mustafa Raoof, Travis E Grotz, Jennifer L Leiting, Keith Fournier, Sean Dineen, Benjamin Powers, Jula Veerapong, Anai Kothari, Ugwuji Maduekew, Shishir Maithel, Gregory C Wilson, Sameer H Patel,…
Read MoreExtracellular Vesicles Isolated from Malignant Mesothelioma Cancer-Associated Fibroblasts Induce Pro-Oncogenic Changes in Healthy Mesothelial Cells
International Journal of Molecular Sciences 2022 October 18 [Link] Tatyana Chernova, Stefano Grosso, Xiao-Ming Sun, Angela Rubio Tenor, Joaquin Zacarias Cabeza, Andrew Craxton, Emily L Self, Apostolos Nakas, Kelvin Cain, Marion MacFarlane, Anne E Willis Abstract Malignant mesothelioma is an aggressive tumour of the pleura (MPM) or peritoneum with a clinical presentation at an advanced…
Read MoreLoss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases
World Journal of Surgical Oncology 2022 October 24 [Link] He-Liang Wu, Zhi-Ran Yang, Yan-Dong Su, Ru Ma, Xue-Mei Du, Ying Gao, Yan Li Abstract Background: Malignant peritoneal mesothelioma (MPM) is a rare malignant tumor with a high mortality rate and extremely poor prognosis. In-depth pathological analysis is essential to assess tumor biological behaviors and explore…
Read MoreCytological Diagnosis of Malignant Mesothelioma: A Case Series
Journal of Cytology 2022 July-September [Link] Sakshi Dahiya, Meeta Singh, Shyama Jain, Bembem Khuraijam, Naman Suroya, Shramana Mandal Abstract Background: Mesotheliomas are neoplasms of the serosal lining of the body cavities. Diagnosis requires a multimodal approach of clinical findings, cytology, and histopathology with immunohistochemistry (IHC). The published sensitivity of cytology for diagnosing mesothelioma ranges from…
Read More